Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neumora Therapeutics, Inc. - Common Stock (NQ: NMRA )

1.385 -0.015 (-1.07%)
Streaming Delayed Price Updated: 12:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Neumora Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'
Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion 
Via Benzinga
Rivian Automotive, Cerence, Nu Skin Enterprises And Other Big Stocks Moving Higher On Friday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Crude Oil Surges 2%; Tesla Shares Plummet
Via Benzinga
Exposures Fossil Fuels
Earnings Scheduled For November 12, 2024
Via Benzinga
Nasdaq Dips Over 100 Points; Unity Software Shares Jump
Via Benzinga
Dow Surges Over 300 Points; US Initial Jobless Claims Decline
Via Benzinga
Topics Stocks
Exposures US Equities
Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops
The company said it plans to investigate a positive signal from female patients. 
Via Investor's Business Daily
Neumora Therapeutics, XPeng And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials
Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and updates are anticipated. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024
NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024
NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?
Neumora Therapeutics faces setbacks as FDA halts Phase 1 trial of NMRA-266 due to convulsion concerns in rabbits. Phase 1 study paused; company working with FDA for resolution. 
Via Benzinga
Exposures Product Safety
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect. 
Via Investor's Business Daily
Why Is Mobile Global Esports (MGAM) Stock Down 18% Today?
Mobile Global Esports stock is falling on Monday after the company revealed that shares of MGAM will be delisted later this week. 
Via InvestorPlace
Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today?
Neumora Therapeutics stock is falling on Monday as investors in NMRA shares react to a clinical trial being put on hold by the FDA. 
Via InvestorPlace
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... 
Via Benzinga
Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On Wednesday
U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023
NMRA stock results show that Neumora Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.